{"id":69672,"date":"2026-07-09T20:54:52","date_gmt":"2026-07-09T12:54:52","guid":{"rendered":"https:\/\/flcube.com\/?p=69672"},"modified":"2026-07-09T20:54:53","modified_gmt":"2026-07-09T12:54:53","slug":"abbvie-secures-european-commission-approval-for-tepkinly-combination-therapy-in-relapsed-refractory-follicular-lymphoma-with-79-reduction-in-disease-progression-risk","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69672","title":{"rendered":"AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AbbVie Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) announced that the <strong>European Commission (EC)<\/strong> has granted <strong>marketing authorization<\/strong> for <strong>TEPKINLY\u00ae (epcoritamab)<\/strong> in combination with <strong>lenalidomide and rituximab (TEPKINLY + R\u00b2)<\/strong> for the treatment of adult patients with <strong>relapsed or refractory (R\/R) follicular lymphoma (FL)<\/strong>. The approval is based on compelling Phase 3 data demonstrating unprecedented efficacy improvements over standard therapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-details\" class=\"wp-block-heading\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>TEPKINLY\u00ae (epcoritamab) + lenalidomide + rituximab (R\u00b2)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adult patients with relapsed or refractory follicular lymphoma<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>6 July 2026<\/td><\/tr><tr><td><strong>Molecule Type<\/strong><\/td><td>Bispecific antibody targeting CD3 (T-cell) and CD20 (B-cell)<\/td><\/tr><tr><td><strong>Supporting Trial<\/strong><\/td><td>Phase 3 EPCORE FL-1 study<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-trial-results-epcore-fl-1-phase-3-study\" class=\"wp-block-heading\">Clinical Trial Results \u2013 EPCORE FL-1 Phase 3 Study<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The open-label, randomized trial compared TEPKINLY + R\u00b2 against R\u00b2 alone in patients with R\/R FL, delivering statistically significant and clinically meaningful outcomes across all key endpoints:<\/p>\n\n\n\n<h3 id=\"h-primary-endpoint-progression-free-survival-pfs\" class=\"wp-block-heading\">Primary Endpoint \u2013 Progression-Free Survival (PFS)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>79% reduction<\/strong> in risk of disease progression or death (HR 0.21, 95% CI: 0.13\u20130.33, p&lt;0.0001)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-secondary-endpoints\" class=\"wp-block-heading\">Secondary Endpoints<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>TEPKINLY + R\u00b2<\/th><th>R\u00b2 Alone<\/th><th>Statistical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Overall Response Rate (ORR)<\/strong><\/td><td>96% (95% CI: 90.2\u201398.6)<\/td><td>81% (95% CI: 72.7\u201387.7)<\/td><td>p&lt;0.0001<\/td><\/tr><tr><td><strong>Complete Response (CR) Rate<\/strong><\/td><td>74% (181\/243, 95% CI: 68.5\u201379.8)<\/td><td>43% (106\/245, 95% CI: 37.0\u201349.7)<\/td><td>p&lt;0.0001<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-safety-profile\" class=\"wp-block-heading\">Safety Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Consistent with known safety profiles of individual regimen components<\/li>\n\n\n\n<li>No new safety signals identified<\/li>\n\n\n\n<li>Manageable adverse event profile supporting outpatient administration potential<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Follicular lymphoma represents approximately 20-30% of all non-Hodgkin lymphomas, with an estimated 15,000-20,000 new cases annually in Europe. Despite advances in treatment, R\/R FL remains challenging to manage, with limited therapeutic options offering durable responses.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">TEPKINLY&#8217;s approval positions AbbVie to compete directly with other bispecific antibodies in development, including Roche&#8217;s mosunetuzumab and Genmab\/Janssen&#8217;s epcoritamab (different molecule), while offering superior efficacy data compared to existing standard-of-care regimens. The subcutaneous administration route provides additional convenience advantages over intravenous alternatives.<\/p>\n\n\n\n<h2 id=\"h-commercial-implications\" class=\"wp-block-heading\">Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Potential:<\/strong> Analysts project peak annual sales of \u20ac800-1.2 billion in the European FL indication alone<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Expected premium pricing reflecting substantial clinical benefit and unmet medical need<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Rapid reimbursement negotiations anticipated given magnitude of clinical benefit<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> U.S. FDA decision expected Q4 2026; additional regulatory submissions planned for Asia-Pacific markets<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance-for-abbvie\" class=\"wp-block-heading\">Strategic Significance for AbbVie<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This approval strengthens AbbVie&#8217;s oncology portfolio beyond its flagship immunology franchise, demonstrating successful execution of its strategy to diversify revenue streams. TEPKINLY represents the company&#8217;s first approved bispecific antibody and establishes a platform for expansion into additional hematologic malignancies, with ongoing trials in diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical trial results, market opportunities, and financial projections. Actual results may differ materially due to competitive pressures, regulatory requirements, market acceptance, and other risk factors detailed in AbbVie&#8217;s SEC filings.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69673,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[234,16,29,853,15],"class_list":["post-69672","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-abbvie","tag-cancer","tag-combination-therapy","tag-nyse-abbv","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for TEPKINLY\u00ae (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R\u00b2) for the treatment of adult patients with relapsed or refractory (R\/R) follicular lymphoma (FL). The approval is based on compelling Phase 3 data demonstrating unprecedented efficacy improvements over standard therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69672\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk\" \/>\n<meta property=\"og:description\" content=\"AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for TEPKINLY\u00ae (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R\u00b2) for the treatment of adult patients with relapsed or refractory (R\/R) follicular lymphoma (FL). The approval is based on compelling Phase 3 data demonstrating unprecedented efficacy improvements over standard therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69672\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-09T12:54:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-09T12:54:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0902.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69672#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69672\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\\\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk\",\"datePublished\":\"2026-07-09T12:54:52+00:00\",\"dateModified\":\"2026-07-09T12:54:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69672\"},\"wordCount\":467,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69672#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0902.webp\",\"keywords\":[\"AbbVie\",\"Cancer\",\"Combination therapy\",\"NYSE: ABBV\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69672#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69672\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69672\",\"name\":\"AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\\\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69672#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69672#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0902.webp\",\"datePublished\":\"2026-07-09T12:54:52+00:00\",\"dateModified\":\"2026-07-09T12:54:53+00:00\",\"description\":\"AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for TEPKINLY\u00ae (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R\u00b2) for the treatment of adult patients with relapsed or refractory (R\\\/R) follicular lymphoma (FL). The approval is based on compelling Phase 3 data demonstrating unprecedented efficacy improvements over standard therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69672#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69672\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69672#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0902.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0902.webp\",\"width\":1080,\"height\":608,\"caption\":\"AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\\\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69672#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\\\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk - Insight, China&#039;s Pharmaceutical Industry","description":"AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for TEPKINLY\u00ae (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R\u00b2) for the treatment of adult patients with relapsed or refractory (R\/R) follicular lymphoma (FL). The approval is based on compelling Phase 3 data demonstrating unprecedented efficacy improvements over standard therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69672","og_locale":"en_US","og_type":"article","og_title":"AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk","og_description":"AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for TEPKINLY\u00ae (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R\u00b2) for the treatment of adult patients with relapsed or refractory (R\/R) follicular lymphoma (FL). The approval is based on compelling Phase 3 data demonstrating unprecedented efficacy improvements over standard therapy.","og_url":"https:\/\/flcube.com\/?p=69672","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-09T12:54:52+00:00","article_modified_time":"2026-07-09T12:54:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0902.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69672#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69672"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk","datePublished":"2026-07-09T12:54:52+00:00","dateModified":"2026-07-09T12:54:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69672"},"wordCount":467,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69672#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0902.webp","keywords":["AbbVie","Cancer","Combination therapy","NYSE: ABBV","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69672#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69672","url":"https:\/\/flcube.com\/?p=69672","name":"AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69672#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69672#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0902.webp","datePublished":"2026-07-09T12:54:52+00:00","dateModified":"2026-07-09T12:54:53+00:00","description":"AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for TEPKINLY\u00ae (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R\u00b2) for the treatment of adult patients with relapsed or refractory (R\/R) follicular lymphoma (FL). The approval is based on compelling Phase 3 data demonstrating unprecedented efficacy improvements over standard therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69672#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69672"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69672#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0902.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0902.webp","width":1080,"height":608,"caption":"AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69672#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed\/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0902.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69672"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69672\/revisions"}],"predecessor-version":[{"id":69674,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69672\/revisions\/69674"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69673"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}